Unconventional Weapon in the War on Cancer Revealed:

Immunicom & Sheba Medical Center Initiate Clinical Trial to Evaluate Breakthrough Oncology Treatment, Immunopheresis™ Therapy

SAN DIEGO and TEL AVIV – July 9, 2020 – Sheba Medical Center at Tel HaShomer and Immunicom,

Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom

LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune

checkpoint inhibitor. Sheba Medical Center, which is located in metro Tel Aviv, Israel, is the largest

medical facility of its kind in the Middle East and was recently ranked as one of the top 10 Best Hospitals

in the World by Newsweek magazine.

“Immunicom is significantly accelerating its evaluation of the Immunopheresis™ therapy by teaming up

with Sheba Medical Center and its’ world-renowned principal oncology investigator, Professor Gal

Markel. This is the first trial where we are combining our novel Immunopheresis therapy with a market-leading checkpoint inhibitor immunotherapy drug,” said Amir Jafri, Founder and CEO, Immunicom, Inc.

Utilizing a process similar to dialysis, Immunopheresis therapy is a non-pharmaceutical solution for

treating cancer by using the LW-02 device to remove the harmful excess of immune-suppressive

cytokines inhibitors produced by cancers to block the natural immune response to kill these tumors. The

LW-02 device has received Breakthrough Device designation for stage IV metastatic cancer from the U.S.

Food and Drug Administration (FDA).

The 40-patient clinical study conceived and led by Principal Investigator, Professor Gal Markel, Director

of the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center, will treat resistant

metastatic melanoma, triple-negative breast cancer, renal cell carcinoma and non-small cell lung cancer

patients.

“Immunicom’s innovative treatment approach neutralizes cancer’s ability to block the patient’s natural

immune defense mechanisms, which are usually exhausted when the patient is suffering from metastatic

disease,” said Markel. “The approach is based on selective extraction of soluble proteins that shield

tumors, to activate the patient’s immune system to fight cancer aggressively. This novel methodology

represents a sea change from traditional standards-of-care and offers the potential for achieving much

better clinical outcomes with fewer treatment side effects. Hagit Harati, head nurse and co-founder of the

newly established Immunopheresis Unit at Sheba, will be responsible of trial execution”.

The trial was made possible via a grant from the Samueli Foundation, which supports integrative health

initiatives in the U.S. and Israel, and funded the establishment of the Integrative Immuno-Oncology

Program (I2O) at Sheba’s Ella Institute, led by Prof. Markel.

Dr. Wayne Jonas, Director of Samueli Foundation’s Integrative Health Program, has had a particular

interest in this therapy’s potentially unique ability to filter out some of the key biologic facilitators of

cancer growth for many years. This drove Jonas and the Samueli Foundation to collaborate with

Immunicom to co-fund Prof. Markel’s clinical evaluation of this novel new immunotherapy approach for

treating cancer.

For an overview of how this breakthrough technology works see: https://www.immunicom.com/how-it-works. Immunopheresis is an investigational therapy that has not yet been approved for use by the FDA

or proven safe and effective for the treatment of any cancers. In addition to this new clinical evaluation of

Immunopheresis at Sheba Medical Center to treat several cancers, Immunopheresis is currently being

evaluated in Poland to treat triple-negative breast cancer (TNBC) in an ongoing clinical trial.

About Sheba Medical Center, Tel HaShomer

Sheba Medical Center, Tel HaShomer is the largest and most comprehensive medical center in the Middle

East. Sheba is the only medical center in Israel that features several hospitals, including an oncology

treatment and research institute on one campus, and is at the forefront of medical treatments, patient care,

research and education. Ella Lemelbaum Institute for Immuno-oncology is a global leader in cancer

immunotherapy. In 2019 and 2020, Newsweek magazine named Sheba one of the top ten hospitals in the

world. To learn more, visit: eng.sheba.co.il.

About Immunicom

Immunicom, Inc. is a privately-held medical technology company located in San Diego, California and

Houston, Texas focused on developing innovative, non-pharmaceutical approaches for treating cancer,

inflammatory diseases, and autoimmune diseases. Immunicom's revolutionary blood-filtering technology

has the potential to effectively treat a wide variety of cancer types including those that have not responded

to other treatment strategies including other drug and biological-based immunotherapy options, with

possibly fewer side effects. The company seeks to leverage its technology to address unmet medical needs

and improve patient access and affordability of cancer and other inflammatory and autoimmune disease

treatments around the world.

6048 CORNERSTONE COURT W

SUITE D, 

SAN DIEGO, CA 92121

General Inquiries

business@immunicom.com

(657) 202-6388

Media Relations

publicrelations@immunicom.com

(657) 202-6040

©2018 Immunicom, Inc. All rights reserved.

  • Black LinkedIn Icon